Quantile regression for survival data in modern cancer research: expanding statistical tools for precision medicine. Issue 2 (18th June 2019)

• Record Type: Journal Article
• Authors: Hong, Hyokyoung G; Christiani, David C; Li, Yi
• Is Part Of: Precision clinical medicine. Volume 2:Issue 2(2019)
• Page Start: 90
• Page End: 99
• Publication Date: 2019-06-18
• Subjects: quantile regression -- lung cancer -- censored outcome -- risk prediction -- CpG methylation -- high-dimensional data analysis; Medicine -- Periodicals; Medical care -- Periodicals; Personalized medicine -- Periodicals; 610
• DOI: 10.1093/pcmedi/pbz007
• Languages: English
• ISSNs: 2096-5303

Abstract

Abstract: Quantile regression links the whole distribution of an outcome to the covariates of interest and has become an important alternative to commonly used regression models. However, the presence of censored data such as survival time, often the main endpoint in cancer studies, has hampered the use of quantile regression techniques because of the incompleteness of data. With the advent of the precision medicine era and availability of high throughput data, quantile regression with high-dimensional predictors has attracted much attention and provided added insight compared to traditional regression approaches. This paper provides a practical guide for using quantile regression for right censored outcome data with covariates of low- or high-dimensionality. We frame our discussion using a dataset from the Boston Lung Cancer Survivor Cohort, a hospital-based prospective cohort study, with the goals of broadening the scope of cancer research, maximizing the utility of collected data, and offering useful statistical alternatives. We use quantile regression to identify clinical and molecular predictors, for example CpG methylation sites, associated with high-risk lung cancer patients, for example those with short survival.